Penumbra Q3 net income falls 8% to $42.28 million; Q3 revenue rises 16% to $410.15 million
- Penumbra's third-quarter 2026 net income fell 8% year over year to $42.28 million.
- Revenue rose 16% year over year to $410.15 million.
- Global thrombectomy revenue climbed 18% year over year to $279.16 million.
- The company will not provide full-year 2026 guidance given its pending acquisition by Boston Scientific.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Penumbra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610291605PR_NEWS_USPR_____SF83735) on October 29, 2026, and is solely responsible for the information contained therein.